Sometimes I think people on this forum are so invested in ICX-TRC that they fail to take a few steps back and realize what Intercytex has accomplished so far. Rather than being overly supportive too many of us are overly critical. Here’s a news article from Cambridge Evening News that has summarized the latest report from Intercytex… and no over-scrutinizing of numbers, no “HM is only for the next generation” announcments, no decrying Intercytex for doing what they said they’d do (release data in 2007 and continue with rolling trials until an effective protocol is developed).
Clinical boon for company
Intercytex, the Cambridge company developing treatments for baldness as well as cell therapy for wound-healing, has reported half year results to June 30 showing a pre-tax loss of £6.04m, compared with £4.04m for the same period last year.
More to the point, the company reported a string of good news relating to the development of its products, including a clinical breakthrough in regenerative medicine for skin grafts, Phase II trial success in facial rejuvenation, especially in treating acne scars, and the first dozen patients treated in a Phase II trial on hair regeneration showing increased hair count.
In the area of chronic wounds, the company is even further ahead, with a Phase III trial on-going and increased in size following review data from the first 108 patients.
Recruitment has now been completed for a trial involving diabetic foot ulcers.
During the period the company also clinched a deal with mighty Baxter Healthcare.
Nick Higgins, ceo, said: “We announced a clinical breakthrough in regenerative medicine in June and we are now seeing this success being repeated across our portfolio.”
26 September 2007